These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 36113532)

  • 21. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
    Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
    Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis.
    D'Addario M; Redmond S; Scott P; Egli-Gany D; Riveros-Balta AX; Henao Restrepo AM; Low N
    Vaccine; 2017 May; 35(22):2892-2901. PubMed ID: 28455170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study.
    Man I; Georges D; de Carvalho TM; Ray Saraswati L; Bhandari P; Kataria I; Siddiqui M; Muwonge R; Lucas E; Berkhof J; Sankaranarayanan R; Bogaards JA; Basu P; Baussano I
    Lancet Oncol; 2022 Nov; 23(11):1419-1429. PubMed ID: 36174583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9-14 years of age: Interim analysis from a phase 3 clinical trial.
    Zaman K; Schuind AE; Adjei S; Antony K; Aponte JJ; Buabeng PB; Qadri F; Kemp TJ; Hossain L; Pinto LA; Sukraw K; Bhat N; Agbenyega T
    Vaccine; 2024 Apr; 42(9):2290-2298. PubMed ID: 38431444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
    Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
    Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial.
    Porras C; Sampson JN; Herrero R; Gail MH; Cortés B; Hildesheim A; Cyr J; Romero B; Schiller JT; Montero C; Pinto LA; Schussler J; Coronado K; Sierra MS; Kim JJ; Torres CM; Carvajal L; Wagner S; Campos NG; Ocampo R; Kemp TJ; Zuniga M; Lowy DR; Avila C; Chanock S; Castrillo A; Estrada Y; Barrientos G; Monge C; Oconitrillo MY; Kreimer AR
    Vaccine; 2022 Jan; 40(1):76-88. PubMed ID: 34857420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune response following a two-dose schedule of bivalent HPV vaccination among girls and boys.
    Middeldorp M; Duijster JW; van de Kassteele J; van der Klis FRM; de Melker HE
    Front Immunol; 2024; 15():1327770. PubMed ID: 38343547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial.
    Barnabas RV; Brown ER; Onono M; Bukusi EA; Njoroge B; Winer RL; Donnell D; Galloway D; Cherne S; Heller K; Leingang H; Morrison S; Rechkina E; McClelland RS; Baeten JM; Celum C; Mugo N;
    Trials; 2021 Sep; 22(1):661. PubMed ID: 34579786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
    Adigweme I; Futa A; Saidy-Jah E; Edem B; Akpalu E; Dibbasey T; Sethna V; Dhere R; Kampmann B; Bengt C; Sirr J; Hosken N; Goldblatt D; Antony K; Alderson MR; Lamola S; Clarke E
    Lancet Infect Dis; 2023 May; 23(5):609-620. PubMed ID: 36638819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study.
    Toh ZQ; Russell FM; Reyburn R; Fong J; Tuivaga E; Ratu T; Nguyen CD; Devi R; Kama M; Matanitobua S; Tabrizi SN; Garland SM; Sinha R; Frazer I; Tikoduadua L; Kado J; Rafai E; Mulholland EK; Licciardi PV
    Clin Infect Dis; 2017 Apr; 64(7):852-859. PubMed ID: 28034886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective cohort study of immunogenicity of quadrivalent human papillomavirus vaccination among Alaska Native Children, Alaska, United States.
    Bruce MG; Meites E; Bulkow L; Panicker G; Hurlburt D; Lecy D; Thompson G; Rudolph K; Unger ER; Hennessy T; Markowitz LE
    Vaccine; 2020 Sep; 38(42):6585-6591. PubMed ID: 32814639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
    Madhi SA; Mutsaerts EA; Izu A; Boyce W; Bhikha S; Ikulinda BT; Jose L; Koen A; Nana AJ; Moultrie A; Roalfe L; Hunt A; Goldblatt D; Cutland CL; Dorfman JR
    Lancet Infect Dis; 2020 Dec; 20(12):1426-1436. PubMed ID: 32857992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.
    Godi A; Bissett SL; Miller E; Beddows S
    PLoS One; 2015; 10(10):e0140926. PubMed ID: 26495976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
    Malagón T; Drolet M; Boily MC; Franco EL; Jit M; Brisson J; Brisson M
    Lancet Infect Dis; 2012 Oct; 12(10):781-9. PubMed ID: 22920953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
    Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
    J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial.
    Kreimer AR; Sampson JN; Porras C; Schiller JT; Kemp T; Herrero R; Wagner S; Boland J; Schussler J; Lowy DR; Chanock S; Roberson D; Sierra MS; Tsang SH; Schiffman M; Rodriguez AC; Cortes B; Gail MH; Hildesheim A; Gonzalez P; Pinto LA;
    J Natl Cancer Inst; 2020 Oct; 112(10):1038-1046. PubMed ID: 32091594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study.
    Sankaranarayanan R; Joshi S; Muwonge R; Esmy PO; Basu P; Prabhu P; Bhatla N; Nene BM; Shaw J; Poli URR; Verma Y; Zomawia E; Pimple S; Tommasino M; Pawlita M; Gheit T; Waterboer T; Sehr P; Pillai MR;
    Vaccine; 2018 Aug; 36(32 Pt A):4783-4791. PubMed ID: 29551226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.